DailyStocks Stock Article Search

https://www.fool.com/investing/2024/03/24/a-once-in-a-generation-investment-opportunity-1-ai/?source=iedfolrf0000001 Mar 24, 2024 - Brookfield Infrastructure offers a unique way to invest in the data infrastructure megatrend. 0

https://www.fool.com/investing/2024/03/24/how-big-will-starlink-become-in-2024/?source=iedfolrf0000001 Mar 24, 2024 - Starlink is getting bigger. It's also getting cheaper. For investors in a Starlink IPO, this is not necessarily a good thing. 0

https://www.denverpost.com/2024/03/22/with-all-the-recent-headlines-about-panels-and-tires-falling-off-planes-is-flying-safe/ Mar 22, 2024 - It's been 15 years since the last fatal crash of a U.S. airliner, but you wouldn't know that from a torrent of flight problems that made news in the last three months. There was a time when things like cracked windshields and minor engine problems didn’t typically receive media coverage. That changed when a panel plugging the space reserved for an unused emergency door blew off an Alaska Airlines jetliner in January. Concern about air safety, especially with Boeing planes, hasn't let up since. U.S. airline executives want to hear how Boeing plans to fix problems with its 737 Max jets. So is flying getting more dangerous? By the roughest measurement, the answer is no. 0

https://www.zacks.com/stock/news/2244198/biotech-stock-roundup-gern-crnx-gain-on-updates-bmy-s-car-t-cell-therapy-news-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2244198 Mar 21, 2024 - Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates. 0

https://seekingalpha.com/news/4081853-bristol-myers-gets-eu-approval-for-abecma-for-multiple-myeloma?source=feed_sector_healthcare Mar 20, 2024 - Bristol Myers (BMY) has received EU regulatory approval for its CAR T-cell therapy Abecma in the treatment of relapsed or refractory multiple myeloma. Read more here. 0

https://www.zacks.com/stock/news/2243567/is-it-wise-to-retain-sba-communications-sbac-stock-for-now?cid=CS-ZC-FT-analyst_blog|zer_report_update-2243567 Mar 20, 2024 - SBA Communications (SBAC) is likely to benefit from the rising global demand for wireless connectivity and its asset buyouts. However, notable customer concentration and high interest rates are key woes. 0

https://www.nrn.com/quick-service/subway-plans-four-sauces-grocery-sales Mar 20, 2024 - Restaurant brand teams with T. Marzetti Co. for scholarship fund benefit 0

https://www.zacks.com/stock/news/2242974/5-reasons-to-invest-in-t-rowe-price-trow-stock-right-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242974 Mar 19, 2024 - T. Rowe Price's (TROW) solid AUM balance, business diversification initiatives, acquisitions and global reach make it an attractive investment option. 0

https://seekingalpha.com/news/4080447-citius-pharmaceuticals-receives-fda-acceptance-of-resubmission-for-its-relapsed-lymphoma-treatment?source=feed_sector_healthcare Mar 18, 2024 - Citius Pharmaceuticals announces FDA acceptance of resubmission for LYMPHIR, a promising immunotherapy for cutaneous T-cell lymphoma treatment. 0

https://seekingalpha.com/article/4678703-poseida-april-2024-data-could-shed-light-on-differentiated-car-t-advancement?source=feed_all_articles Mar 16, 2024 - Poseida is expected to release results from the phase 1 study using P-BCMA-ALLO1 on April 8th, 2024. Read why PSTX stock is a Buy. 0